Click to Share
 

Diabetes Clinical Study Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By Avail Clinical Research
Avail is conducting a 6-week, Phase 2 randomized study to assess the safety, tolerability and pharmacodynamics of a new combination therapy administered to participants with type 2 diabetes mellitus.
By Achieve Clinical Research
A 26-week, multi-center, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naive subjects with Type 2 Diabetes. The total duration of the trial is approximately 29 weeks.
By Avail Clinical Research
This study is a Phase 1, Placebo-Controlled, Randomized Trial to Assess the Safety and Tolerability of a New Drug in Obese Hyperlipidemic Adults with or without Type 2 Diabetes
By Achieve Clinical Research
This trial is a 26-week, multi-center, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naïve subjects with T2DM inadequately controlled on a maximum tolerated dose or maximum dose according to label of GLP-1.
By Achieve Clinical Research
The primary objective of this 22 week study is to investigate the change in glycosylated hemoglobin (HbA1c) after receiving the new drug, as compared to those receiving a placebo.

Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share